RLS-0071

DRUG4 trials

Sponsors

ReAlta Life Sciences, Inc.

Conditions

Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseHealthy VolunteerHypoxic-Ischemic EncephalopathySteroid Refractory GVHD

Phase 1

A Phase 1 SAD/MAD Study of RLS-0071 in Healthy Volunteers in Support of a COVID-19 Development Program

CompletedNCT05298787

ReAlta Life Sciences, Inc.Healthy Volunteer

Start: 2021-01-13End: 2021-08-16Updated: 2022-03-28

Phase 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

RecruitingNCT05778188

ReAlta Life Sciences, Inc.Hypoxic-Ischemic Encephalopathy

Start: 2023-07-27End: 2028-12-01Target: 70Updated: 2026-04-13

Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Active, not recruitingNCT06175065

ReAlta Life Sciences, Inc.Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Start: 2024-01-25End: 2025-06-30Target: 24Updated: 2025-05-08

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

RecruitingNCT06343792

ReAlta Life Sciences, Inc.Steroid Refractory GVHD

Start: 2024-08-31End: 2026-12-31Target: 66Updated: 2025-11-24

Related Papers

Pegtarazimod limits acute graft-versus-host disease mortality and severity in mice and is tolerated in patients.

2026-08-04

Anti-inflammatory drug pegtarazimod (RLS-0071) demonstrates clinical improvement in lower gastrointestinal acute graft-versus-host disease (aGvHD) and target engagement of key inflammatory marker myeloperoxidase (MPO)

Blood2025-11-03

Exploring a Novel Anti-Inflammatory Peptide As a Potential Treatment for Acute Graft-Versus-Host Disease (aGVHD)

Blood2024-11-05